Boston Scientific (BSX) slides after management cuts 2026 growth outlook

Boston Scientific Corporation (BSX) is down 10.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied to management dialing back its 2026 outlook and flagging softer near-term growth in key franchises, which likely reset investor expectations for the year. Concerns around competitive pressure in electrophysiology and a slowdown in WATCHMAN procedures looked like the central issues.

Details:

Management reduced full-year 2026 organic growth guidance to 6.5% to 8% and set second-quarter guidance at 5% to 7% during an investor presentation.

The updated outlook cited slower standalone WATCHMAN growth, with commentary implying a flatter growth profile across the middle quarters.

Electrophysiology expectations were also trimmed, with competitive launches highlighted as a headwind even as the company aimed to defend its pulsed-field ablation positioning.

Separately, a recent FDA Class I recall classification for a correction affecting certain ACCOLADE-family pacemakers and CRT-Ps has been in the background, which could be adding incremental sentiment pressure (this could be because recall headlines can amplify risk-off trading even when financial impact is unclear).

Sources:

Investing.com, U.S. Food and Drug Administration (FDA), Boston Scientific

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BSX Insider Trading Activity

$BSX insiders have traded $BSX stock on the open market 7 times in the past 6 months. Of those trades, 4 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:

MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 2 sales selling 160,901 shares for an estimated $15,043,394.
ARTHUR C BUTCHER (EVP& Grp Pres, MedSurg & APAC) sold 17,313 shares for an estimated $1,758,188
DAVID C HABIGER has made 2 purchases buying 4,450 shares for an estimated $251,098 and 0 sales.
EDWARD J LUDWIG purchased 3,580 shares for an estimated $202,914
CHERYL PEGUS purchased 1,770 shares for an estimated $99,987

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BSX Hedge Fund Activity

We have seen 846 institutional investors add shares of $BSX stock to their portfolio, and 998 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 23,160,546 shares (-23.8%) from their portfolio in Q1 2026, for an estimated $1,433,869,402
CAPITAL WORLD INVESTORS removed 11,841,837 shares (-43.6%) from their portfolio in Q1 2026, for an estimated $733,128,128
WELLINGTON MANAGEMENT GROUP LLP added 9,124,317 shares (+94.0%) to their portfolio in Q1 2026, for an estimated $564,886,465
FRANKLIN RESOURCES INC added 8,822,659 shares (+155.4%) to their portfolio in Q1 2026, for an estimated $546,210,818
FISHER ASSET MANAGEMENT, LLC removed 8,687,613 shares (-95.1%) from their portfolio in Q1 2026, for an estimated $537,850,120
TWO SIGMA INVESTMENTS, LP added 6,939,887 shares (+280.8%) to their portfolio in Q1 2026, for an estimated $429,648,404
MILLENNIUM MANAGEMENT LLC removed 6,926,986 shares (-61.5%) from their portfolio in Q1 2026, for an estimated $428,849,703

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BSX Government Contracts

We have seen $23,676,031 of award payments to $BSX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

THERASPHERE Y-90 GLASS MICROSPHERE MEDICATION: $1,260,000
Y90 GLASS MICROSPHERES: $1,227,000
Y90 THERASPHERE: $1,155,000
VAPAHCS THERASPHERE Y90 RADIOPHARMACEUTICALS: $954,240
THERASPHERE YTTIRUM-90 (Y-90) GLASS: $833,910

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$BSX Congressional Stock Trading

Members of Congress have traded $BSX stock 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $30,000 on 02/10, 01/30 and 1 sale worth up to $15,000 on 12/24.
SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
SENATOR JOHN BOOZMAN sold up to $15,000 on 12/17.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BSX Analyst Ratings

Wall Street analysts have issued reports on $BSX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 02/05/2026
Truist Securities issued a "Buy" rating on 02/05/2026
BTIG issued a "Buy" rating on 02/04/2026
RBC Capital issued a "Outperform" rating on 12/17/2025

To track analyst ratings and price targets for $BSX, check out Quiver Quantitative's $BSX forecast page.

$BSX Price Targets

Multiple analysts have issued price targets for $BSX recently. We have seen 21 analysts offer price targets for $BSX in the last 6 months, with a median target of $87.0.

Here are some recent targets:

David Rescott from Baird set a target price of $75.0 on 05/19/2026
Bob Hopkins from B of A Securities set a target price of $68.0 on 05/18/2026
Mike Matson from Needham set a target price of $77.0 on 05/18/2026
Marie Thibault from BTIG set a target price of $80.0 on 05/18/2026
Larry Biegelsen from Wells Fargo set a target price of $75.0 on 04/23/2026
William Plovanic from Canaccord Genuity set a target price of $71.0 on 04/23/2026
Vijay Kumar from Evercore ISI Group set a target price of $78.0 on 04/23/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.